Department of Engineering and Architecture, University of Trieste, Via Alfonso Valerio, 6/A, I-34127 Trieste, Italy.
Laboratory of Bioinorganic Chemistry, Department of Pharmacy and Biotechnology, University of Bologna, I-40127 Bologna, Italy.
Molecules. 2018 Mar 28;23(4):777. doi: 10.3390/molecules23040777.
Despite the advances in anticancer therapies, their effectiveness for many human tumors is still far from being optimal. Significant improvements in treatment efficacy can come from the enhancement of drug specificity. This goal may be achieved by combining the use of therapeutic molecules with tumor specific effects and delivery carriers with tumor targeting ability. In this regard, nucleic acid-based drug (NABD) and particularly small interfering RNAs (siRNAs), are attractive molecules due to the possibility to be engineered to target specific tumor genes. On the other hand, polymeric-based delivery systems are emerging as versatile carriers to generate tumor-targeted delivery systems. Here we will focus on the most recent findings in the selection of siRNA/polymeric targeted delivery systems for hepatocellular carcinoma (HCC), a human tumor for which currently available therapeutic approaches are poorly effective. In addition, we will discuss the most attracting and, in our opinion, promising siRNA-polymer combinations for HCC in relation to the biological features of HCC tissue. Attention will be also put on the mathematical description of the mechanisms ruling siRNA-carrier delivery, this being an important aspect to improve effectiveness reducing the experimental work.
尽管癌症治疗方法已经取得了进展,但它们对许多人类肿瘤的疗效仍然远非理想。治疗效果的显著提高可以通过增强药物的特异性来实现。这一目标可以通过将治疗分子与肿瘤特异性效应以及具有肿瘤靶向能力的输送载体结合来实现。在这方面,基于核酸的药物(NABD),特别是小干扰 RNA(siRNA),是一种很有吸引力的分子,因为可以对其进行工程设计以靶向特定的肿瘤基因。另一方面,基于聚合物的输送系统作为多功能载体正在出现,以生成肿瘤靶向输送系统。在这里,我们将重点介绍最近在选择用于肝细胞癌(HCC)的 siRNA/聚合物靶向输送系统方面的发现,HCC 是一种目前治疗方法效果不佳的人类肿瘤。此外,我们还将讨论与 HCC 组织的生物学特征有关的、针对 HCC 最具吸引力和最有前途的 siRNA-聚合物组合。我们还将关注控制 siRNA-载体输送的机制的数学描述,这是提高疗效、减少实验工作的重要方面。